NeuroXess Raises 700 Million Yuan in Series B to Push 'Three-Comprehensive' BCI Into Clinical Trials

Chinese brain-computer interface company NeuroXess has secured 700 million yuan in Series B financing, marking one of the largest single funding rounds in the global BCI sector this year. The capital injection arrives at a pivotal moment for the company, as its flagship "Three-Comprehensive" brain-computer interface system has formally entered registration clinical trials — the regulatory stage that must be cleared before a device can receive market approval in China.

The Technology

The "Three-Comprehensive" designation reflects NeuroXess's stated ambition to build a BCI platform that is comprehensive in signal coverage, comprehensive in application scenarios, and comprehensive in its integration of hardware and software. Unlike narrow-use implantable devices designed around a single therapeutic indication, the architecture is engineered to support a range of neural recording and stimulation tasks within a unified system. Entering registration clinical trials means the device has already passed earlier feasibility and safety checkpoints, and the company is now generating the controlled human data that Chinese regulators at the National Medical Products Administration require before granting formal approval for clinical deployment. This milestone puts NeuroXess in a small cohort of companies globally that have advanced fully implantable BCI hardware to this stage of human evaluation.

Market Context

The scale of this funding round signals intensifying domestic competition within China's rapidly expanding neurotech sector, as well as growing confidence among Chinese institutional investors in the commercial viability of implantable neural interfaces. The round arrives against a backdrop of active government-level interest in standardising and accelerating BCI development across the country. For international observers, the NeuroXess raise reinforces a pattern that has become impossible to ignore: Chinese BCI companies are no longer operating in a developmental shadow of their Western counterparts but are instead running parallel, well-capitalised programmes at comparable technical stages. Western firms including Neuralink's competitors and a growing field of venture-backed startups now face a global competitive landscape in which Chinese players have both regulatory familiarity on home turf and access to deep pools of patient capital.

What's Next

With 700 million yuan now secured, NeuroXess is positioned to scale its clinical trial infrastructure, expand its engineering and neuroscience teams, and begin laying the commercial groundwork that will be necessary once regulatory clearance is obtained. The registration trial phase will be closely watched by clinicians, regulators, and competitors alike, as its outcomes will shape not only the company's trajectory but the broader credibility of implantable BCIs as a therapeutic category in the world's largest healthcare market. If the trials proceed successfully, the approval of a Chinese-developed implantable BCI system would represent a defining inflection point for the global neurotechnology industry.